62813-01-8

Usage

Uses

1-Cyclopropylpiperidin-4-one

InChI:InChI=1/C8H13NO/c10-8-3-5-9(6-4-8)7-1-2-7/h7H,1-6H2

Upstream product

• 49683-17-2 3-[cyclopropyl-(2-ethoxycarbonyl-ethyl)-amino]-propionic acid ethyl ester 
• 76377-76-9 1-Cyclopropyl-4-methoxy-piperidin-4-ol 
• 765-30-0 Cyclopropylamine 
• 49681-84-7 ethyl 1-cyclopropyl-4-oxopiperidine-3-carboxylate 
• 41661-47-6 piperidin-4-one 
• 4333-56-6 cyclopropyl bromide 
• 77542-18-8 1-methyl-1-ethyl-4-oxopiperidinium iodide 

Downstream Products

• 163632-24-4 1-cyclopropyl-4-o-tolyl-piperidin-4-ol 
• 1001345-77-2 N-benzyl-1-cyclopropyl-piperidin-4-amine 
• 851847-62-6 1-cyclopropylpiperidin-4-ol 
• 62813-02-9 1-Cyclopropyl-piperidin-4-ylamine 
• 1361569-79-0 7-(1-cyclopropylpiperidin-4-yl)-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-7,9-dihydro-8H-purin-8-one 
• 1361570-30-0 N⁵-(1-cyclopropylpiperidin-4-yl)-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidine-4,5-diamine 
• 713147-47-8 1-cyclopropyl piperidine-4-carbonitrile 

Relevant academic research and scientific papers

Small Molecule Stimulators of Steroid Receptor Coactivator-3 and Methods of Their Use as Cardioprotective and/or Vascular Regenerative Agents

Small molecule stimulators of steroid receptor coactivator-3 (SRC-3) and methods of their use as cardioprotective agents are provided. The small molecule stimulators are useful for promoting cardiac protection and repair and vascular regeneration after my

Compounds with antiviral and bacteriostatic activity

The invention discloses a structural design and a synthesis method of compounds with antiviral and bacteriostatic activity. The invention particularly relates to a series of compounds which are obtained by taking piperidine pyrazole boric acid as a main body structure and performing structural modification on the piperidine pyrazole boric acid, so that the compounds become chemical synthetic drugswith the potential of being developed into antibacterial agents or antiviral drugs. The patent content comprises a synthetic route and a synthetic method of the compounds designed for the structure.

5-Hydroxyindole-2-carboxylic acid amides: Novel histamine-3 receptor inverse agonists for the treatment of obesity

Obesity is a major risk factor in the development of conditions such as hypertension, hyperglycemia, dyslipidemia, coronary artery disease, and cancer. Several pieces of evidence across different species, including primates, underscore the implication of the histamine 3 receptor (H3R) in the regulation of food intake and body weight and the potential therapeutic effect of H3R inverse agonists. A pharmacophore model, based on public information and validated by previous investigations, was used to design several potential scaffolds. Out of these scaffolds, the 5-hydroxyindole-2-carboxylic acid amide appeared to be of great potential as a novel series of H3R inverse agonist. Extensive structure-activity relationships revealed the interconnectivity of microsomal clearance and hERG (human ether-a-go-go-related gene) affinity with lipophilicity, artificial membrane permeation, and basicity. This effort led to the identification of compounds reversing the (R)-R-methylhistamine-induced water intake increase in Wistar rats and, further, reducing food intake in diet-induced obese Sprague-Dawley rats. Of these, the biochemical, pharmacokinetic, and pharmacodynamic characteristics of (4,4-difluoropiperidin- 1-yl)[1-isopropyl-5-(1-isopropylpiperidin-4-yloxy)-1H-indol-2-yl]-methanone 36 are detailed.

NOVEL COMPOUNDS

There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.

5-Aminoindole derivatives as H3 inverse agonists

The present invention relates to compounds of formula I wherein R1, R2, R3, R4 and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

NAPHTHALINE DERIVATIVES USEFUL AS HISTAMINE-3-RECEPTOR LIGANDS

The present invention relates to compounds of formula (I) wherein A, R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, to the preparation of such compounds and pharmaceutical compositions containing them. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, to the preparati

AMIDE DERIVATIVES

The invention concerns a compound of the Formula (I) wherein m is 0-2 and each R1 is a group such as hydroxy, halogeno, trifluoromethyl heterocyclyl and heterocyclyloxy; R2 is halogeno, trifluoromethyl or (1-6C)alkyl; R3 is hydrogen, halogeno or (1-6C)alkyl; and R4 is (3-6C)cycloalkyl;or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical condions mediated by cytokines.

Novel indolobenzazepine derivatives, useful as tranquilizers

Certain novel 1,2,3,4,8,9-hexahydro-3-(substituted)pyrido[4',3':2,3]indolo[1,7-ab][1]-benzazepines are useful as minor tranquilizers (anxiolytics) and/or major tranquilizers (antipsychotics). The minor tranquilizers are effective at non-ataxic doses, and are not likely to cause addiction when abused. A representative compound in this class is 3-(cyclopropylmethyl)-1,2,3,4,8,9-hexahydropyrido[4',3':2,3]indolo[1,7-ab][1]benzazepine.